DYRK1A and myeloproliferative neoplasm: To investigate the effect of DYRK1A on the leukemia-propagating capacity of JAK2 mutant BP-MPN cell lines in vivo, we performed CRISPR-mediated DYRK1A KO in luciferase-tagged SET2 and HEL cell lines and compared their leukemogenic capacity in xenografts using immunodeficient mice (Fig. 5h–k).